10
Participants
Start Date
February 2, 2022
Primary Completion Date
December 2, 2024
Study Completion Date
February 2, 2025
Trabectedin
Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
Pioglitazone Oral Product
Patients will be treated with Trabectedin administered at a dose of 1.5 mg/m2-1.3 mg/m2 (according to investigator's choice, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access every 3 weeks and pioglitazone given continuously at the daily dose of 45 mg by oral route.
RECRUITING
Fondazione IRCCS Istituto Nazionale Tumori, Milan
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER
Humanitas Hospital, Italy
OTHER
Mario Negri Institute for Pharmacological Research
OTHER